Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Reviews on Recent Clinical Trials
  4. Volume 20, Issue 1
  5. Article
Volume 20, Issue 1
  • ISSN: 1574-8871
  • E-ISSN: 1876-1038

Abstract

Management of infections in heart transplant recipients is complex and crucial. In this population, there is a need for a better understanding of immunosuppressive trough levels (C0), infectious complications, and urinary tract infections (UTIs). The purpose of this review was to understand the association between immunosuppressive trough levels and UTIs after heart transplantation. A review of scientific literature (n= 100) was conducted based on the topic of interest by searching PUBMED.Gov (https://pubmed.ncbi.nlm.nih.gov/), Web of Science, and Scopus. The analysis of bacterial pulmonary infection required the occurrence of new or deteriorating pulmonary infiltrates and the development of organisms in cultures of sputum specimens. The diagnosis of UTIs was based on the result of related signs, pyuria, and a positive urine culture. The incidence of UTIs was reported as 0.07 episodes/1000 regarding heart transplantation days. An eightfold increase in the rate of rejection was noted in heart transplant recipients with higher variability in tacrolimus C0. There are associations between C0 of immunosuppressive drugs and clinical presentation of infection complications. Recipients with a low metabolism of immunosuppressive drugs are more susceptible to infectious complications. Attention to the biology of herpes viruses, and after heart transplantation are important, in which some of them are the most common pathogens responsible for UTIs. Pneumocystis and cytomegalovirus affect all transplant recipients. Pneumonia due to bacterial, viral, protozoa, and fungal infections, in addition to UTIs, are more specific reported types of infections in heart transplant recipients. Bacterial infections produced by extensively drug-resistant Enterobacteriaceae, vancomycin-resistant enterococci, and non-fermenting gram-negative bacteria were reported to increase after transplantation.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/rrct/10.2174/0115748871315445240916091528
2024-09-25
2025-05-30

  • From This Site

    /content/journals/rrct/10.2174/0115748871315445240916091528
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ColvinMM SmithJM AhnYS HandarovaDK MartinezAC LindbladKA IsraniAK SnyderJJ OPTN/SRTR 2022 annual data report: Heart.Am J Transplant.2024242S1S305S39310.1016/j.ajt.2024.01.016
     [Google Scholar]
  2. AlraiesM.C. EckmanP. Adult heart transplant: Indications and outcomes.J. Thorac. Dis.2014681120112810.3978/j.issn.2072‑1439.2014.06.4425132979
     [Google Scholar]
  3. Henao-MartínezAF MontoyaJG Infections in heart, lung, and heart-lung transplantation. Principles and practice of transplant infectious diseasesBerlin, HeidelbergSpringerLink201810.1007/978‑1‑4939‑9034‑4_2
     [Google Scholar]
  4. StinsonE.B. BieberC.P. GrieppR.B. ClarkD.A. ShumwayN.E. RemingtonJ.S. Infectious complications after cardiac transplantation in man.Ann. Intern. Med.1971741223610.7326/0003‑4819‑74‑1‑224923804
     [Google Scholar]
  5. HaddadF. DeuseT. PhamM. KhazanieP. RossoF. LuikartH. ValantineH. LeonS. VuT.A. HuntS.A. OyerP. MontoyaJ.G. Changing trends in infectious disease in heart transplantation.J. Heart Lung Transplant.201029330631510.1016/j.healun.2009.08.01819853478
     [Google Scholar]
  6. PonsS. SonnevilleR. BouadmaL. StyfalovaL. RucklyS. NeuvilleM. RadjouA. LebutJ. DillyM.P. MourvillierB. DorentR. NatafP. WolffM. TimsitJ.F. Infectious complications following heart transplantation in the era of high-priority allocation and extracorporeal membrane oxygenation.Ann. Intensive Care2019911710.1186/s13613‑019‑0490‑230684052
     [Google Scholar]
  7. MluguE.M. MohamediJ.A. SangedaR.Z. MwambeteK.D. Prevalence of urinary tract infection and antimicrobial resistance patterns of uropathogens with biofilm forming capacity among outpatients in morogoro, Tanzania: A cross-sectional study.BMC Infect. Dis.202323166010.1186/s12879‑023‑08641‑x37798713
     [Google Scholar]
  8. GillenJ.R. IsbellJ.M. MichaelsA.D. LauC.L. SawyerR.G. Risk factors for urinary tract infections in cardiac surgical patients.Surg. Infect. (Larchmt.)201516550450810.1089/sur.2013.11526115336
     [Google Scholar]
  9. MedinaM. Castillo-PinoE. An introduction to the epidemiology and burden of urinary tract infections.Ther. Adv. Urol.20191110.1177/175628721983217231105774
     [Google Scholar]
  10. StrohaekerJ. AschkeV. KoenigsrainerA. NadalinS. BachmannR. Urinary tract infections in kidney transplant recipients—is there a need for antibiotic stewardship?J. Clin. Med.202111122610.3390/jcm1101022635011966
     [Google Scholar]
  11. ArabiZ. Al ThiabK. AltheabyA. AboalsamhG. KashkoushS. AlmarastaniM. ShaheenM.F. AltamimiA. O’haliW. Bin SaadK. AlnajjarL. AlhusseinR. AlmuhitebR. AlqahtaniB. AlotaibiR. AlqahtaniM. TawhariM. Urinary tract infections in the first 6 months after renal transplantation.Int. J. Nephrol.202120211810.1155/2021/303327634820141
     [Google Scholar]
  12. VidalE. CerveraC. CorderoE. ArmiñanzasC. CarrataláJ. CisnerosJ.M. FariñasM.C. López-MedranoF. MorenoA. MuñozP. OrigüenJ. SabéN. ValerioM. Torre-CisnerosJ. Management of urinary tract infection in solid organ transplant recipients: Consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI).Enferm. Infecc. Microbiol. Clin.20153310679.e1679.e2110.1016/j.eimc.2015.03.02425976754
     [Google Scholar]
  13. WadhawanM. GuptaC. Immunosuppression Monitoring—What Clinician Needs to Know?J. Clin. Exp. Hepatol.202313469169710.1016/j.jceh.2023.01.00337440936
     [Google Scholar]
  14. OlenskiS. ScuderiC. ChooA. Bhagat SinghA.K. WayM. JeyaseelanL. JohnG. Urinary tract infections in renal transplant recipients at a quaternary care centre in Australia.BMC Nephrol.201920147910.1186/s12882‑019‑1666‑631881863
     [Google Scholar]
  15. GiordanoL.F.C. LasmarM.F. ViannaH.R. LasmarL.F. PalmaR.V.S. DomicianoJ.Jr LasmarE.P. Risk factors related to urinary tract infection in renal transplant recipients: 539.Transplantation20129410S84910.1097/00007890‑201211271‑01669
     [Google Scholar]
  16. LakshmiV. MohanM.V.N.L.R. NeerajaM. SudhaharanS. RajuS.B. GangadharT. Risk factors for urinary tract infections in renal allograft recipients: Experience of a tertiary care center in Hyderabad, South India.Indian J. Nephrol.201727537237610.4103/ijn.IJN_331_1628904433
     [Google Scholar]
  17. HookerD.G.K. FosterK. DodsonA. Multi-drug resistant urinary tract infections following renal transplant: Risk factors and patient outcomes.Am. J. Transplant.2017173
     [Google Scholar]
  18. ShaheenF.A. BasriN. MohammedZ. AbdullahK. HaiderR. AwadA. NasserA. El GabartyA. Experience of renal transplantation at the king fahd hospital, Jeddah, Saudi Arabia.Saudi J. Kidney Dis. Transpl.200516456257218202511
     [Google Scholar]
  19. AlkatheriM. Urinary tract infections in Saudi renal transplant recipients.J. Infect. Dis. Immun.201352182310.5897/JIDI12.026
     [Google Scholar]
  20. AlkatheriA.M. AlbekairyA.M. AlharbiS. AldekhaelS.N. KhalidiN. AlsayyariA.A. Abdel-RazaqW.S. QandilA.M. Investigation of the effectiveness of antibacterial prophylaxis in renal transplant recipients.J. Infect. Dev. Ctries.20148101244125110.3855/jidc.520225313599
     [Google Scholar]
  21. RazonableR.R. FindlayJ.Y. O’RiordanA. BurroughsS.G. GhobrialR.M. AgarwalB. DavenportA. GropperM. Critical care issues in patients after liver transplantation.Liver Transpl.201117551152710.1002/lt.2229121384524
     [Google Scholar]
  22. San-JuanR. AguadoJ.M. LumbrerasC. FortunJ. LenO. MunozP. MontejoM. MorenoA. CorderoE. BlanesM. RamosA. Torre-CisnerosJ. López-MedranoF. CarratalaJ. MorenoE. Selective intestinal decontamination with fluoroquinolones for the prevention of early bacterial infections after liver transplantation.Liver Transpl.201117889690410.1002/lt.2228421351242
     [Google Scholar]
  23. SantithanmakornC. VanichananJ. TownamchaiN. JutivorakoolK. WattanatornS. SutherasanM. OpanurukJ. KerrS.J. PraditpornsilpaK. AvihingsanonY. UdomkarnjananunS. Bacterial urinary tract infection and early asymptomatic bacteriuria in kidney transplantation still negatively affect kidney transplant outcomes in the era of modern immunosuppression and cotrimoxazole prophylaxis.Biomedicines20221011298410.3390/biomedicines1011298436428552
     [Google Scholar]
  24. PrasannakumarP GaddeAB BansalSB RupaliP Expert group opinion for respiratory infections in solid organ transplant recipients in South Asia.Indian J. Transplant.202216Suppl 1S98S10510.4103/ijot.ijot_85_21
     [Google Scholar]
  25. ImlayH. SpellbergB. Shorter is better: The case for short antibiotic courses for common infections in solid organ transplant recipients.Transpl. Infect. Dis.2022245e1389610.1111/tid.1389636254512
     [Google Scholar]
  26. Tolou-GhamariZ. Tacrolimus and cyclosporin pharmacotherapy, detection methods, cytochrome p450 enzymes after heart transplantation.Cardiovasc. Hematol. Agents Med. Chem.202322210611310.2174/187152572166623072615002137496131
     [Google Scholar]
  27. Tolou-GhamariZ. Investigation of nosocomial urinary tract infections post transplantation, main pathogens, and sensitivity tests.Curr. Drug Ther.202419784685010.2174/0115748855271275231115064229
     [Google Scholar]
  28. Tolou GhamariZ. PalizbanA.A. Tacrolimus pharmacotherapy: Infectious complications and toxicity in organ transplant recipients; an updated review.Curr. Drug Res. Rev.202320237324010.2174/012589977525932623121207324038151846
     [Google Scholar]
  29. Tolou-GhamariZ MortazaviM PalizbanAA NajafiMR The investigation of the correlation between iminoral concentration and neurotoxic levels after kidney transplantation.Adv. Biomed. Res.201545910.4103/2277‑9175.151876
     [Google Scholar]
  30. Tolou-GhamariZ. PalizbanA.A. Michael TredgerJ. Clinical monitoring of tacrolimus after liver transplantation using pentamer formation assay and microparticle enzyme immunoassay.Drugs R D.200451172210.2165/00126839‑200405010‑0000314725486
     [Google Scholar]
  31. Tolou-GhamariZ SaneiB. Prograf concentrations in liver transplantation: Correlation with headache and other neurotoxic complications?Thrita J. Neuron201651e32670
     [Google Scholar]
  32. Tolou-GhamariZ Monitoring heart transplant recipients in order to investigate immunosuppressive drug absorption using pharmacokinetics parameters and its’ correlation with nephrotoxicity.AJECR20196434
     [Google Scholar]
  33. Rangel-UgarteP.M. Ramirez-CastañedaS. Mendoza-LopezA.C. Gonzalez-HermosilloL.M. Flores-CalderonO. Salazar-HernandezI. Ramirez-CastañedaA. Roldan-ValadezE. Evolution and current circumstances of heart transplants: Global and mexican perspective.Curr. Probl. Cardiol.2022471010131610.1016/j.cpcardiol.2022.10131635817156
     [Google Scholar]
  34. StolfN.A.G. History of heart transplantation: A hard and glorious journey.Rev. Bras. Cir. Cardiovasc.201732542342710.21470/1678‑9741‑2017‑050829211224
     [Google Scholar]
  35. BarnardC.N. The operation. A human cardiac transplant: An interim report of a successful operation performed at Groote Schuur Hospital, Cape Town.S. Afr. Med. J.19674148127112744170370
     [Google Scholar]
  36. EverlyM.J. Cardiac transplantation in the United States: An analysis of the UNOS registry.Clin. Transpl.20082008354319708444
     [Google Scholar]
  37. BakhtiyarS.S. SakowitzS. MallickS. CurryJ. BenharashP. Heart transplantation after donation after circulatory death: Early United States experience.Ann. Thorac. Surg.2024118248449310.1016/j.athoracsur.2024.05.01338815848
     [Google Scholar]
  38. PilchN.A. BowmanL.J. TaberD.J. Immunosuppression trends in solid organ transplantation: The future of individualization, monitoring, and management.Pharmacotherapy202141111913110.1002/phar.248133131123
     [Google Scholar]
  39. Tolou_GhamariZ. Monitoring tacrolimus after liver transplantation; consideration of alternative techniques and the influence of clinical status.LondonKing’s College1999
     [Google Scholar]
  40. Tolou-GhamariZ. PalizbanA.A. TredgerJ.M. Modelling tacrolimus AUC in acute and chronic liver disease immediately after transplant. Transplantationsmedizin.Organ der Deutschen Transplantationsgesellschaft2004162109111
     [Google Scholar]
  41. Tolou-GhamariZ. PalizbanA.A. WendonJ. TredgerJ.M. Pharmacokinetics of tacrolimus immediately after liver transplantation. Transplantationsmedizin.Organ der Deutschen Transplantationsgesellschaft2004162112116
     [Google Scholar]
  42. SrinivasTR Meier-KriescheHU Minimizing immunosuppression, an alternative approach to reducing side effects: Objectives and interim result.Clin J Am Soc Nephrol.20083 Suppl 2Suppl 2S1011610.2215/CJN.03510807
     [Google Scholar]
  43. Tolou-GhamariZ. Nephro and neurotoxicity of calcineurin inhibitors and mechanisms of rejections: A review on tacrolimus and cyclosporin in organ transplantation.J. Nephropathol.201211233010.5812/jnp.624475383
     [Google Scholar]
  44. ChangD.H. YounJ.C. DiliberoD. PatelJ.K. KobashigawaJ.A. Heart transplant immunosuppression strategies at cedars-sinai medical center.Int. J. Heart Fail.202131153010.36628/ijhf.2020.003436263111
     [Google Scholar]
  45. GuetaI. MarkovitsN. Yarden-BilavskyH. RaichlinE. FreimarkD. LaveeJ. LoebsteinR. PeledY. High tacrolimus trough level variability is associated with rejections after heart transplant.Am. J. Transplant.201818102571257810.1111/ajt.1501629989311
     [Google Scholar]
  46. AbhisekP.A. SrivastavaA. PradhanS. An idiosyncratic reaction of unilateral common peroneal nerve palsy associated with below desired therapeutic range of tacrolimus level in a patient postheart transplantation.Indian J. Pharmacol.202254645946110.4103/ijp.ijp_950_2036722558
     [Google Scholar]
  47. De GregoriS. De SilvestriA. CattadoriB. RapagnaniA. AlbertiniR. NovelloE. ConcardiM. ArbustiniE. PellegriniC. Therapeutic drug monitoring of tacrolimus-personalized therapy in heart transplantation: New strategies and preliminary results in endomyocardial biopsies.Pharmaceutics2022146124710.3390/pharmaceutics1406124735745819
     [Google Scholar]
  48. GodinasL. DobbelsF. HulstL. VerbeeckI. De ConinckI. BerrevoetsP. SchaeversV. YserbytJ. DupontL.J. VerledenS.E. VanaudenaerdeB.M. CeulemansL.J. Van RaemdonckD.E. NeyrinckA. VerledenG.M. VosR. Once daily tacrolimus conversion in lung transplantation: A prospective study on safety and medication adherence.J. Heart Lung Transplant.202140646747710.1016/j.healun.2021.02.01733840608
     [Google Scholar]
  49. NnaniD.U. CampbellA. AjaimyM. SaeedO. PatelS.R. AhmedS. GrahamJ.A. JordeU.P. Effect of glecaprevir/pibrentasvir on weight-adjusted tacrolimus trough/dose ratios in heart and kidney transplant recipients.Transpl. Infect. Dis.2021235e1371610.1111/tid.1371634407270
     [Google Scholar]
  50. SilvaJ.T. AguadoJ.M. Current state of antimicrobial stewardship and organ transplantation in Spain.Transpl. Infect. Dis.2022245e1385110.1111/tid.1385135579889
     [Google Scholar]
  51. Hosseini-MoghaddamS.M. LuoB. BotaS.E. HusainS. SilvermanM.S. DanemanN. BrownK.A. PatersonJ.M. Incidence and outcomes associated with clostridioides difficile infection in solid organ transplant recipients.JAMA Netw. Open2021412e214108910.1001/jamanetworkopen.2021.4108934964852
     [Google Scholar]
  52. FakhredineS OravecT BelgaS WrightA MahA, MD Management of common infections in solid organ transplant recipients in British Columbia.BCMJ2022644166173
     [Google Scholar]
  53. EscribanoP. Rodríguez-SánchezB. Díaz-GarcíaJ. Martín-GómezM.T. Ibáñez-MartínezE. Rodríguez-MayoM. PeláezT. García-Gómez de la PedrosaE. Tejero-GarcíaR. MarimónJ.M. ReigadasE. RezustaA. Labayru-EcheverríaC. Pérez-AyalaA. AyatsJ. CoboF. PazosC. López-SoriaL. Alastruey-IzquierdoA. MuñozP. GuineaJ. Sánchez-YebraW. Sánchez-GómezJ. LozanoI. MarfilE. Muñoz de la RosaM. GarcíaR.T. CoboF. CastroC. LópezC. RezustaA. PeláezT. Castelló-AbietarC. CostalesI. SerraJ.L. JiménezR. EcheverríaC.L. PérezC.L. Megías-LobónG. LorenzoB. Sánchez-ReusF. AyatsJ. MartínM.T. VidalI. Sánchez-HellínV. IbáñezE. PemánJ. FajardoM. PazosC. Rodríguez-MayoM. Pérez-AyalaA. GómezE. GuineaJ. EscribanoP. SerranoJ. ReigadasE. RodríguezB. ZvezdanovaE. Díaz-GarcíaJ. Gómez-NúñezA. LeivaJ.G. MachadoM. MuñozP. Sánchez-RomeroI. García-RodríguezJ. Luis del PozoJ. VallejoM.R. Ruiz de Alegría-PuigC. López-SoriaL. MarimónJ.M. VicenteD. Fernández-TorresM. Hernáez-CrespoS. Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain.Clin. Microbiol. Infect.20212781170.e11170.e710.1016/j.cmi.2020.09.04233010446
     [Google Scholar]
  54. Cintra-CabreraM. Suárez-BenjumeaA. Bernal-BlancoG. González-RonceroF.M. Toapanta-GaiborN.G. Súñer-PobletM. Pérez-ValdiviaM.Á. Fernández-CuencaF. Gentil-GovantesM.Á. Rocha-CastillaJ.L. Resistant cytomegalovirus infection after renal transplantation: Literature review.Transplant. Proc.201850257557710.1016/j.transproceed.2017.09.05829579856
     [Google Scholar]
  55. GoldmanJ.D. JulianK. Urinary tract infections in solid organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.Clin. Transplant.2019339e1350710.1111/ctr.1350730793386
     [Google Scholar]
  56. KrawczykB. WysockaM. MichalikM. GołębiewskaJ. Urinary tract infections Caused by K. pneumoniae in kidney transplant recipients – epidemiology, virulence and antibiotic resistance.Front. Cell. Infect. Microbiol.20221286137410.3389/fcimb.2022.86137435531341
     [Google Scholar]
  57. KorzeniowskiO.M. Urinary tract infection in the impaired host.Med. Clin. North Am.199175239140410.1016/S0025‑7125(16)30461‑81996041
     [Google Scholar]
  58. FischerK. HamzaA. EismannR. AmouryM. HeynemannH. FornaraP. Differential diagnostic use of interleukin patterns in patients being monitored after transplantation.Clin. Chim. Acta20013101718010.1016/S0009‑8981(01)00525‑311485758
     [Google Scholar]
  59. BodroM. SanclementeG. LipperheideI. AllaliM. MarcoF. BoschJ. CofanF. RicartM.J. EsforzadoN. OppenheimerF. MorenoA. CerveraC. Impact of urinary tract infections on short-term kidney graft outcome.Clin. Microbiol. Infect.201521121104.e11104.e810.1016/j.cmi.2015.07.01926235196
     [Google Scholar]
  60. Morales-AlvarezM.C. Nephrotoxicity of antimicrobials and antibiotics.Adv. Chronic Kidney Dis.2020271313710.1053/j.ackd.2019.08.00132146999
     [Google Scholar]
  61. PesceF. MartinoM. FiorentinoM. RolloT. SimoneS. GalloP. StalloneG. GrandalianoG. SchenaA. MargiottaM. MininniD. PalieriR. LucarelliG. BattagliaM. GesualdoL. CastellanoG. Recurrent urinary tract infections in kidney transplant recipients during the first-year influence long-term graft function: A single-center retrospective cohort study.J. Nephrol.201932466166810.1007/s40620‑019‑00591‑530701457
     [Google Scholar]
  62. CoxL. HeC. BevinsJ. ClemensJ.Q. StoffelJ.T. CameronA.P. Gentamicin bladder instillations decrease symptomatic urinary tract infections in neurogenic bladder patients on intermittent catheterization.Can. Urol. Assoc. J.2017119E350E35410.5489/cuaj.443429382457
     [Google Scholar]
  63. KimJ.Y.V. AssadianS. HollanderZ. BurnsP. ShannonC.P. LamK. TomaM. IgnaszewskiA. DaviesR.A. DelgadoD. HaddadH. IsaacD. KimD. MuiA. RajdaM. WestL. WhiteM. ZierothS. KeownP.A. McMasterW.R. NgR.T. McManusB.M. LevingsM.K. TebbuttS.J. RegulatoryT. Regulatory T Cell Biomarkers identify patients at risk of developing acute cellular rejection in the first year following heart transplantation.Transplantation202310781810181910.1097/TP.000000000000460737365692
     [Google Scholar]
  64. ChengY. ChenJ. LinX. QiuH. ZhangJ. Population pharmacokinetic analysis for model-based therapeutic drug monitoring of tacrolimus in chinese han heart transplant patients.Eur. J. Drug Metab. Pharmacokinet.20234818910010.1007/s13318‑022‑00807‑336482138
     [Google Scholar]
  65. KhatriB. MaharjanS. LamsalJ. KhatriB. Singh ShahD. Urinary tract infection among post-renal transplant patients in the department of nephrology of a tertiary care centre: A descriptive cross-sectional study.JNMA J. Nepal Med. Assoc.20226025050751010.31729/jnma.749635690975
     [Google Scholar]
  66. AlangadenG.J. ThyagarajanR. GruberS.A. MorawskiK. GarnickJ. El-AmmJ.M. WestM.S. SillixD.H. ChandrasekarP.H. HaririanA. Infectious complications after kidney transplantation: Current epidemiology and associated risk factors.Clin. Transplant.200620440140910.1111/j.1399‑0012.2006.00519.x16842513
     [Google Scholar]
  67. VerouxM. GiuffridaG. CoronaD. GaglianoM. ScriffignanoV. VizcarraD. TallaritaT. ZerboD. VirgilioC. SciaccaA. CappelloD. StefaniS. VerouxP. Infective complications in renal allograft recipients: Epidemiology and outcome.Transplant. Proc.20084061873187610.1016/j.transproceed.2008.05.06518675076
     [Google Scholar]
  68. NajarM.S. SaldanhaC.L. BandayK.A. Approach to urinary tract infections.Indian J. Nephrol.200919412913910.4103/0971‑4065.5933320535247
     [Google Scholar]
  69. Moysés NetoM. CostaR.S. ReisM.A. FerrazA.S. SaberL.T. BatistaM.E. MugliaV. GarciaT.M. FigueiredoJ.F. Use of ciprofloxacin as a prophylactic agent in urinary tract infections in renal transplant recipients.Clin. Transplant.1997115 Pt 14464529361939
     [Google Scholar]
  70. Rosado-CantoR. Parra-AvilaI. Tejeda-MaldonadoJ. Kauffman-OrtegaC. Rodriguez-CovarrubiasF.T. Trujeque-MatosM. Cruz-MartínezR. Maravilla-FrancoE. Criollo-MoraE. Arreola-GuerraJ.M. Morales-BuenrostroL.E. Sifuentes-OsornioJ. Perioperative fosfomycin disodium prophylaxis against urinary tract infection in renal transplant recipients: A randomized clinical trial.Nephrol. Dial. Transplant.202035111996200310.1093/ndt/gfz26131883327
     [Google Scholar]
  71. HollyerI. IsonM.G. The challenge of urinary tract infections in renal transplant recipients.Transpl. Infect. Dis.2018202e1282810.1111/tid.1282829272071
     [Google Scholar]
  72. Ariza-HerediaE.J. BeamE.N. LesnickT.G. KremersW.K. CosioF.G. RazonableR.R. Urinary tract infections in kidney transplant recipients: Role of gender, urologic abnormalities, and antimicrobial prophylaxis.Ann. Transplant.20131819520410.12659/AOT.88390123792521
     [Google Scholar]
  73. FiorentinoM. PesceF. SchenaA. SimoneS. CastellanoG. GesualdoL. Updates on urinary tract infections in kidney transplantation.J. Nephrol.201932575176110.1007/s40620‑019‑00585‑330689126
     [Google Scholar]
  74. GarzoniC. VergidisP. Methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus infections in solid organ transplantation.Am. J. Transplant.201313Suppl. 4505810.1111/ajt.1209823464998
     [Google Scholar]
  75. KullarR. DavisS.L. LevineD.P. ZhaoJ.J. CrankC.W. SegretiJ. SakoulasG. CosgroveS.E. RybakM.J. High-dose daptomycin for treatment of complicated gram-positive infections: A large, multicenter, retrospective study.Pharmacotherapy201131652753610.1592/phco.31.6.52721923436
     [Google Scholar]
  76. ChuangY.C. WangJ.T. LinH.Y. ChangS.C. Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: Systematic review and meta-analysis.BMC Infect. Dis.201414168710.1186/s12879‑014‑0687‑925495779
     [Google Scholar]
  77. SalehipourM. SalahiH. FathikalajahiA. MohammadianR. EmadmarvastiV. BahadorA. NikeghbalianS. KazemiK. DehghaniM. Malek-HosseiniS.A. Is perioperative intravesically applied antibiotic solution effective in the prophylaxis of urinary tract infections after renal transplantation?Urol. Int.2010851666910.1159/00029630320299778
     [Google Scholar]
  78. SweissH. BhayanaS. HallR. NelsonJ. KincaideE. Methenamine for recurrent urinary tract infections in solid organ transplantation.Prog. Transplant.2022321677210.1177/1526924821106488034859711
     [Google Scholar]
  79. KritikosA. ManuelO. Bloodstream infections after solid-organ transplantation.Virulence20167332934010.1080/21505594.2016.113927926766415
     [Google Scholar]
  80. ParasuramanR. JulianK. Urinary tract infections in solid organ transplantation.Am. J. Transplant.201313Suppl. 432733610.1111/ajt.1212423465025
     [Google Scholar]
  81. JinM. ZengL. ZhangW. DengX. LiJ. ZhangW. Clinical features of multidrug-resistant organism infections in early postoperative solid organ transplantation in a single center.Ann. Palliat. Med.20211044555456210.21037/apm‑21‑77733966403
     [Google Scholar]
  82. BhadauriaD. JainS. PrasadR. GurjarM. YacchaM. ShanmughamS. KaulA. Rungmei MarakS.K. NathA. PrasadN. Aetiology, management, and outcome of lower respiratory tract infection in renal allograft recipients – A report from a tropical country.Lung India202239654555210.4103/lungindia.lungindia_99_2236629234
     [Google Scholar]
  83. FalagasM.E. VouloumanouE.K. SamonisG. VardakasK.Z. Fosfomycin.Clin. Microbiol. Rev.201629232134710.1128/CMR.00068‑1526960938
     [Google Scholar]
  84. OnoK. IshibashiY. KanameS. Successful kidney and hematopoietic stem cell transplantation for malignant lymphoma from different donors: A case report and literature review.Transplant. Proc.20225461589159310.1016/j.transproceed.2022.05.00535840432
     [Google Scholar]
  85. Suárez FernándezM.L. Ridao CanoN. Álvarez SantamartaL. Gago FraileM. BlakeO. Díaz CorteC. A current review of the etiology, clinical features, and diagnosis of urinary tract infection in renal transplant patients.Diagnostics (Basel)2021118145610.3390/diagnostics1108145634441390
     [Google Scholar]
  86. StanglFP GodlyJ KranzJ NeumannT SchneidewindL Do we need to treat asymptomatic bacteriuria in immunocompromised patients?: A rapid review.Urologie202362660961410.1007/s00120‑023‑02059‑8
     [Google Scholar]
  87. GaineyA.B. DanielsR. BurchA.K. HawnJ. FacklerJ. BiswasB. BrownsteinM.J. Recurrent ESBL Escherichia coli urosepsis in a pediatric renal transplant patient treated with antibiotics and bacteriophage therapy.Pediatr. Infect. Dis. J.2023421434610.1097/INF.000000000000373536201671
     [Google Scholar]
  88. CruzA.T. TanverdiM.S. SwartzS.J. DayanP.S. CombsV.A. LubellT.R. Frequency of bacteremia and urinary tract infection in pediatric renal transplant recipients.Pediatr. Infect. Dis. J.20224112997100310.1097/INF.000000000000370136102710
     [Google Scholar]
  89. LysZ. DombrovskáK. DědochováJ. KovářováP. ValkovskýI. VáclavíkJ. Acute infections in kidney transplant recipients.Vnitr. Lek.2022683E12E1710.36290/vnl.2022.04136208913
     [Google Scholar]
  90. WuX WuL WanQ Pathogen distribution and risk factors of bacterial and fungal infections after liver transplantation.Zhong Nan Da Xue Xue Bao Yi Xue Ban20224781120112810.11817/j.issn.1672‑7347.2022.220054
     [Google Scholar]
  91. HarrisT.N. SzempruchK.R. DupuisR.E. Serrano RodriguezP. ToledoA.H. Alemtuzumab in renal retransplantation – transplant outcomes and associated infections.Transplant. Proc.202153102888289410.1016/j.transproceed.2021.08.05634774310
     [Google Scholar]
  92. HuangX. ZhouY. ZhangJ. XiangH. MeiH. LiuL. TongL. ZengF. HuangY. ZhouH. ZhangY. The importance of CYP2C19 genotype in tacrolimus dose optimization when concomitant with voriconazole in heart transplant recipients.Br. J. Clin. Pharmacol.202288104515452510.1111/bcp.1538535508605
     [Google Scholar]
  93. ShahA. NasrullahA. ButtM.A. YoungM. Paxlovid with Caution: Novel case of paxlovid-induced tacrolimus toxicity in a cardiac transplant patients.Eur. J. Case Rep. Intern. Med.2022991110.12890/2022_00352836299835
     [Google Scholar]
  94. DériM. Szakál-TóthZ. FeketeF. MangóK. InczeE. MinusA. MerkelyB. SaxB. MonostoryK. CYP3A-status is associated with blood concentration and dose-requirement of tacrolimus in heart transplant recipients.Sci. Rep.20211112138910.1038/s41598‑021‑00942‑y34725418
     [Google Scholar]
  95. TsujiM. KakudaN. BujoC. IshidaJ. AmiyaE. HatanoM. ShimadaA. ImaiH. ShimadaS. KinoshitaO. YamauchiH. OnoM. KomuroI. Sarcopenia and risk of infection in adult heart transplant recipients in Japan.ESC Heart Fail.2022921413142310.1002/ehf2.1383535146960
     [Google Scholar]
  96. Martin-GandulC. MuellerN.J. PascualM. ManuelO. The impact of infection on chronic allograft dysfunction and allograft survival after solid organ transplantation.Am. J. Transplant.201515123024304010.1111/ajt.1348626474168
     [Google Scholar]
  97. KozuchJ.M. BurtC. AfsharK. AslamS. YungG. MariskiM. GoltsE. FeistA. Difference in immunosuppressant dose requirement when transitioning to isavuconazole from other azoles in thoracic transplant recipients.Transpl. Infect. Dis.2024261e1420910.1111/tid.1420938059638
     [Google Scholar]
  98. RomanoL. NapolitanoL. CrocettoF. SciorioC. SioM.D. MirandaA. RomanoM. PriadkoK. Prostate and gut: Any relationship? A narrative review on the available evidence and putative mechanisms.Prostate202484651352410.1002/pros.2467538353479
     [Google Scholar]
  99. Tolou-GhamariZ. WendonJ. TredgerJ.M. In vitro pentamer formation as a biomarker of tacrolimus-related immunosuppressive activity after liver transplantation.Clin Chem Lab Med.200038111209121110.1515/CCLM.2000.19011156362
     [Google Scholar]
  100. HYPERLINK "https://www.scopus.com/authid/detail.uri?authorId=6603144440&eid=2-s2.0-1042304276"Tolou-Ghamari Z, HYPERLINK "https://www.scopus.com/authid/detail.uri?authorId=56177794500&eid=2-s2.0-1042304276"Palizban AA. Laboratory Monitoring of Cyclosporine Pre-Dose Concentration (C0) after Kidney Transplantation in Isfahan. IJMS. 2003 Jun; 28(2): 81-85.
/content/journals/rrct/10.2174/0115748871315445240916091528
Loading
Review of Association between Urinary Tract Infections and Immunosuppressive Drugs after Heart Transplantation
Rev. Recent Clin. Trials 20, 18 (2025); https://doi.org/10.2174/0115748871315445240916091528
/content/journals/rrct/10.2174/0115748871315445240916091528
/content/journals/rrct/10.2174/0115748871315445240916091528
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): cardiac; heart transplantation; immunosuppressive drugs; metabolism; trough levels; Urinary tract infections

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test